Countering Communist China Act

Summary

Countering Communist China Act This bill addresses issues related to China, tax incentives, and other topics. The bill imposes visa- and property-blocking sanctions on certain entities and individuals that (1) are involved in acts of malign disinformation on behalf of a foreign government or political party, or (2) have engaged in a pattern of significant infringement of intellectual property belonging to a U.S. entity or individual. It also authorizes sanctions on developers and owners of software that makes unauthorized transmissions of user data to servers that are located in China and are accessible by China's government. The bill also provides tax incentives for relocating pharmaceutical, medical supply, or medical device manufacturing to the United States, including by allowing accelerated depreciation of nonresidential real property acquired in connection with such relocation; eliminates the five-year amortization requirement for research and experimental expenditures scheduled to begin in 2022, thus allowing continued expensing of such expenditures in the taxable years in which they are incurred; prohibits an institution of higher education from receiving certain federal funds if the institution has a contractual partnership with an entity controlled by China's government or organized under China's laws; modifies presumptions and evidentiary standards in administrative patent validity challenges; bars China from asserting sovereign immunity in certain instances; requires U.S. representatives to the International Monetary Fund (IMF) to take certain actions, such as opposing any increase to the weight given to China's currency when determining the value of IMF Special Drawing Rights; and permanently rescinds unobligated funds previously made available for certain economic relief programs related to COVID-19.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 29 July 2021

   Referred

   Referred to the Subcommittee on Trade.

   Source: Committee

2. 29 July 2021

   Introduced

   Referred to the Committee on Foreign Affairs, and in addition to the Committees on the Judiciary, Ways and Means, Oversight and Reform, Financial Services, Energy and Commerce, Intelligence (Permanent Select), Agriculture, Rules, Transportation and Infrastructure, Science, Space, and Technology, Natural Resources, Education and Labor, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

3. 29 July 2021

   Introduced

   Introduced in House

   Source: IntroReferral

4. 29 July 2021

   Introduced

   Introduced in House

   Source: IntroReferral

5. 30 July 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

6. 4 August 2021

   Referred

   Referred to the Subcommittee on Asia, the Pacific, Central Asia and Nonproliferation.

   Source: Committee

7. 3 September 2021

   Referred

   Referred to the Subcommittee on Energy and Mineral Resources.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 29 July 2021 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 29 July 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 29 July 2021

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 29 July 2021

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Sen. Banks, Jim [R-IN] · R · Sponsor
• Rep. Babin, Brian [R-TX-36] · R · Sponsor
• Rep. Steube, W. Gregory [R-FL-17] · R · Sponsor
• Rep. Wilson, Joe [R-SC-2] · R · Sponsor
• Lisa McClain · R · Sponsor
• Mike Garcia · R · Sponsor
• Rep. Fitzgerald, Scott [R-WI-5] · R · Sponsor
• Rep. Hinson, Ashley [R-IA-2] · R · Sponsor
• Rep. Norman, Ralph [R-SC-5] · R · Sponsor
• Rep. Keller, Fred [R-PA-12] · R · Sponsor
• Rep. Duncan, Jeff [R-SC-3] · R · Sponsor
• Rep. Bergman, Jack [R-MI-1] · R · Sponsor
• Rep. Murphy, Gregory F. [R-NC-3] · R · Sponsor
• Rep. Crenshaw, Dan [R-TX-2] · R · Sponsor
• Rep. Rouzer, David [R-NC-7] · R · Sponsor
• Rep. Stefanik, Elise M. [R-NY-21] · R · Sponsor
• Rep. Tiffany, Thomas P. [R-WI-7] · R · Sponsor
• Rep. Palazzo, Steven M. [R-MS-4] · R · Sponsor
• Rep. Scott, Austin [R-GA-8] · R · Sponsor
• Madison Cawthorn · R · Sponsor
• Rep. Johnson, Mike [R-LA-4] · R · Sponsor
• Rep. Harshbarger, Diana [R-TN-1] · R · Sponsor
• Rep. Tenney, Claudia [R-NY-24] · R · Sponsor
• Rep. Rose, John W. [R-TN-6] · R · Sponsor
• Rep. Johnson, Dusty [R-SD-At Large] · R · Sponsor
• Rep. Barr, Andy [R-KY-6] · R · Sponsor
• Rep. Green, Mark E. [R-TN-7] · R · Sponsor
• Rep. Higgins, Clay [R-LA-3] · R · Sponsor
• Rep. Hartzler, Vicky [R-MO-4] · R · Sponsor
• Rep. LaMalfa, Doug [R-CA-1] · R · Sponsor
• Rep. Burchett, Tim [R-TN-2] · R · Sponsor
• Rep. Hern, Kevin [R-OK-1] · R · Sponsor
• Rep. Reschenthaler, Guy [R-PA-14] · R · Sponsor
• Rep. Arrington, Jodey C. [R-TX-19] · R · Sponsor
• Rep. Hill, J. French [R-AR-2] · R · Cosponsor
• Rep. Feenstra, Randy [R-IA-4] · R · Cosponsor
• Rep. Gooden, Lance [R-TX-5] · R · Cosponsor
• Rep. Van Duyne, Beth [R-TX-24] · R · Cosponsor
• Rep. Good, Bob [R-VA-5] · R · Cosponsor
• Rep. Cline, Ben [R-VA-6] · R · Cosponsor
• Rep. Miller, Mary E. [R-IL-15] · R · Cosponsor
• Rep. Williams, Roger [R-TX-25] · R · Cosponsor
• Rep. Lesko, Debbie [R-AZ-8] · R · Cosponsor
• Rep. Gimenez, Carlos A. [R-FL-28] · R · Cosponsor
• Rep. Davidson, Warren [R-OH-8] · R · Cosponsor
• Rep. Allen, Rick W. [R-GA-12] · R · Cosponsor
• Rep. Cammack, Kat [R-FL-3] · R · Cosponsor
• Rep. Jackson, Ronny [R-TX-13] · R · Cosponsor

Showing 48 of 70 sponsors and actors.

Related records

• related to → Establishing the Joint Select Committee on the Events and Activities Surrounding China's Handling of the 2019 Novel Coronavirus.
• related to → CCP Visa Disclosure Act of 2021
• related to → To prohibit the use of funds to seek membership in the World Health Organization or to provide assessed or voluntary contributions to the World Health Organization.
• related to → Safe Career Transitions for Intelligence and National Security Professionals
• related to → Opposing Business with Chinese Military Companies Act
• related to → American Innovation and R&D Competitiveness Act of 2021
• related to → Keep Huawei on the Entity List Act
• related to → Red Tape Reduction Act
• related to ← Protecting Personal Data from Foreign Adversaries Act
• related to ← To amend section 1603 of title 28, United States Code, to except the People's Republic of China as a defined foreign state.
• related to ← CCP Businesses Registered Agent Act
• related to ← Holding Countries Accountable for Negligent Chemical and Biological Programs Act
• related to ← Exposing China’s Belt and Road Investment in America Act of 2021
• related to ← Exposing China’s Belt and Road Investment in America Act of 2021
• related to ← To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.

Showing 15 of 33 related records.